Erythema Migrans
12
2
2
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (12)
Patient's Pretreatment Expectations About Post-Lyme Symptoms
Different Amoxicillin Treatment Regimens in Erythema Migrans Patients
Lyme Borreliosis and Early Cutaneous Diagnostic
Next Generation Sequencing Detection of Lyme Disease
Inflammatory Mediators in Erythema Migrans
Inflammatory Responses in Solitary and Multiple Erythema Migrans
Erythema Migrans in Elderly
Cytokines and Chemokines in Erythema Migrans
Analysis of Lyme Disease Lesions
Culture Media for Borrelia Burgdorferi Sensu Lato
Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome